Table 1.
Patient demographics.
| Discovery dataset (TCGA CRC, n = 359) | Validation dataset (GSE39582, n = 566) | |
|---|---|---|
| Gender | ||
| Male | 194 (54%) | 310 (55%) |
| Female | 165 (46%) | 256 (45%) |
| Age (years) | ||
| Median (IQR) | 66 (55-74.5) | 68.1 (59-76) |
| >65 vs. ≤65 | 184 vs. 175 | 342 vs. 124 |
| Stage | ||
| I | 56 | 37∗ |
| II | 134 | 264 |
| III | 116 | 205 |
| IV | 53 | 60 |
| KRAS status | ||
| Wild type | 217 (60%) | 328 (58%) |
| Mutant | 142 (40%) | 217 (39%) |
| N/A | — | 21 (3%) |
| BRAF status | ||
| Wild type | 307 (86%) | 461 (82%) |
| Mutant | 52 (14%) | 51 (9%) |
| N/A | — | 54 (9%) |
| TP53 status | ||
| Wild type | 140 (39%) | 161 (28%) |
| Mutant | 219 (61%) | 190 (34%) |
| N/A | — | 215 (38%) |
| OS | ||
| Median | 22.4 (months) | 51 (months) |
| Range | 0-150 (months) | 0-201 (months) |
| Event/nonevent | 77/282 | 191/371 |
| PFI or RFS∗∗ | ||
| Median | 19.6 (months) | 43 (months) |
| Range | 0-150 (months) | 0-201 (months) |
| Event/nonevent | 100/259 | 177/380 |